Celebrex Generic Exclusivity Suit Could Have Broad Financial, Regulatory Reach

Appeals court says FDA violated Hatch-Waxman by awarding 180-day exclusivity solely to Teva based on reissued patent; celecoxib generics are already marketed but could step out from Pfizer-authorized status.